When AI-Based Image Analysis Gets in Clinical Trials

ESMO 2021 -- Especially during the COVID-19 pandemic, implementation and development of whole slide scanning lead to an active growth of digital pathology and image analysis (IA). In the present study, we conducted a global evaluation of three markers on breast invasive carcinomas: estrogen receptor (ER), progesterone receptor (PR) and Ki67 as a proliferation marker. The aim was to study the correlation between pathologist conventional semi quantitative scoring method on glass and scanned slides versus artificial intelligence-based IA scoring. We discuss potential future opportunities introducing AI in clinical trials for tissue biomarkers evaluation.

Filed In

Breast cancer
Digital Pathology